News Quantified

TVRD – tvardi therapeutics, inc. (US:NASDAQ)

Tvardi Therapeutics (TVRD) had its "sell (e+)" rating reaffirmed by Weiss Ratings.

4/3

07:22 am

tvrd

Low

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium [Yahoo! Finance]

Tvardi Therapeutics (TVRD) had its "buy" rating reaffirmed by BTIG Research. They now have a $15.00 price target on the stock.

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Tvardi Therapeutics (TVRD) had its price target lowered by Barclays PLC from $5.00 to $4.00. They now have an "equal weight" rating on the stock.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}